Protecting Democracy [1]

American democracy is in jeopardy, from the disastrous Citizens United ruling that flooded our politics with corporate cash to the immoral assault on voting rights. We work every day to defend against these threats and advance bold reforms.

Overturn Citizens United Now

Sign the Petition

Generative Artificial Intelligence and Threats to Democracy

Protecting Elected Officials from Threats
Making Government Work [2]

The U.S. government should work for the public, not corporations or industry. It should safeguard consumers, workers and the environment, and be funded well enough to do so. The budget process must not be obstructed by partisanship.

Get Corporate Money Out of Politics

Sign the Petition

It’s Time to Cut the Bloated Pentagon Budget to Fund People, Not Military Contractors

Ensuring Public Money Does Not Go To Private Equity
Consumer & Worker Safeguards [3]

Every day, Big Banks, Big Polluters, and Big Tech companies are threatening our economy, our environment, and our democracy – sacrificing Main Street Americans and our families on the altar of corporate profits. Public Citizen advocates for ordinary people by taking on corporate interests and their cronies in government.

Don’t Let Big Tech Write Our Digital Privacy Laws

Sign Now

Trump Guts Enforcement, Greenlights Corporate Crime Spree

Trump’s Executive Order Aims to Illegally Undermine Federal Independent Agencies, Shield Big Corporations from Accountability
Safe & Affordable Drugs & Devices [4]

Prescription drugs are unaffordable and new drugs and devices often are approved without being proven safe and effective. Public Citizen challenges Big Pharma, device manufacturers and federal regulators to make drugs and medical devices safe, effective and accessible to all.

Join the Movement

Get Involved
Health Care [5]

Health care in the U.S. leaves too many people out, costs too much and doesn’t meet acceptable standards of quality. Much of the care that we get is unaffordable, unnecessary or harmful. Public Citizen advocates Medicare for All, stronger oversight of dangerous doctors and safe clinical trials.

Win Medicare for All

Take Action Now

Report: The Trump Administration’s Stop-Work Order and Funding Freeze likely affected 32 USAID-Funded Clinical Trials

Public Citizen Petitions OSHA and CMS to Implement Work-Hour Regulations for Resident Physicians
Globalization & Trade [6]

As Public Citizen’s division fighting for a fairer global economy, Global Trade Watch works to expose and challenge trade policies that put corporate profits over people.

Under Donald Trump, that mission faces a new urgency. Trump has won two elections in part by exploiting working people’s real frustrations about an increasingly complex and unequal global economy, yet his trade agenda serves only himself and his billionaire allies.

Global Trade Watch seeks to hold him accountable, resist corporate rollbacks, and advance a global trade vision that uplifts workers across borders.

Learn more about our work.

Join the Trade Justice Movement

JOIN NOW
Climate & Energy [7]

The climate crisis is the challenge of our time. We can fix it with solutions that will make us healthier and more economically secure. We must act quickly to make our economy run on renewable power — and ensure that disadvantaged families and displaced workers share equitably in the new economy. We also must fight the corrupting power of fossil fuel companies and ensure that energy regulators are effective and publicly accountable.

Tell Toyota: Go all-in on EVs

Add Your Name

Climate Roadmap for U.S. Financial Regulation

Trump’s Polluter Playground: Fossil Fuel Insiders & Ideologues Prop Up Dirty Energy & Derail Clean Power
Justice & the Courts [8]

Litigation can remedy or deter wrongdoing, impact policy and meaningfully slow abuses of power. Whether suing on behalf of our members to ensure the honest functioning of government, or representing individual consumers seeking redress in court, our litigation draws on our expertise in administrative law, constitutional law, and government transparency.

Subscribe to the Supreme Court Conference Preview

Sign Up

February 1, 1994

Complaint for Declaratory and Injunctive Relief to compel the production of all records distributed by the FDA to its advisory committees in preparation for the advisory committees’ discussion on Oralet (transmucosal fentanyl)

View as PDF

Topics

Safe & Affordable Drugs & Devices: Drugs

Stay Updated on Public Citizen

Follow Public Citizen

Support Our Work

Donate

Menu

Overturn Citizens United Now

Generative Artificial Intelligence and Threats to Democracy

Protecting Elected Officials from Threats

Get Corporate Money Out of Politics

It’s Time to Cut the Bloated Pentagon Budget to Fund People, Not Military Contractors

Ensuring Public Money Does Not Go To Private Equity

Don’t Let Big Tech Write Our Digital Privacy Laws

Trump Guts Enforcement, Greenlights Corporate Crime Spree

Trump’s Executive Order Aims to Illegally Undermine Federal Independent Agencies, Shield Big Corporations from Accountability

Join the Movement

Win Medicare for All

Report: The Trump Administration’s Stop-Work Order and Funding Freeze likely affected 32 USAID-Funded Clinical Trials

Public Citizen Petitions OSHA and CMS to Implement Work-Hour Regulations for Resident Physicians

Join the Trade Justice Movement

Tell Toyota: Go all-in on EVs

Climate Roadmap for U.S. Financial Regulation

Trump’s Polluter Playground: Fossil Fuel Insiders & Ideologues Prop Up Dirty Energy & Derail Clean Power

Subscribe to the Supreme Court Conference Preview

Share

Complaint for Declaratory and Injunctive Relief to compel the production of all records distributed by the FDA to its advisory committees in preparation for the advisory committees’ discussion on Oralet (transmucosal fentanyl)

Share

Topics

You might be interested in

Letter to Congress Opposing Certain Provisions of S. 1895, the Lower Health Care Costs Act

Letter to Congress Opposing Section 207 of S. 1895, the Lower Health Care Costs Act

Comments on the FDA’s Draft Guidance for Industry Entitled “Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework”

Comments on the FDA’s Proposal to Change the Approval Package Documentation Posted on the Agency’s Website For New Drugs and Biologics

Stay Updated on Public Citizen

Follow Public Citizen

Support Our Work